Drugs News and Research

RSS

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

As reform hangs in balance, policy benefits continue to be discussed

NPR reports on the immediate effects of the proposed health care bill, and that Congressional Democrats are focusing on those benefits in messages to constituents. "The White House is trying to shift the conversation away from the messy legislative process — which Republicans are keying on — and instead focus on what the health care overhaul would do for families and businesses."

19 Mar 2010

Acne drug prevents HIV breakout

Johns Hopkins scientists have found that a safe and inexpensive antibiotic in use since the 1970s for treating acne effectively targets infected immune cells in which HIV, the virus that causes AIDS, lies dormant and prevents them from reactivating and replicating.

18 Mar 2010

Health care fraud, prescription theft lead to significant losses

ABC News: "A four month 'Nightline' investigation into Medicare fraud makes one thing perfectly clear: this is a crime that pays and pays and pays. The federal government admits that a staggering $60 billion is stolen from tax payers through Medicare scams every year. Some experts believe the number is more than twice that.

18 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Therapeutic may not be effective on trauma patients with undiagnosed Helicobacter infections

A Kansas State University study aimed at alleviating intestinal damage in trauma patients digressed to an important finding that could affect medication given to the individuals.

18 Mar 2010

Study finds the cost of cancer care is skyrocketing

USA Today: "The cost of cancer treatment is 'skyrocketing' — both for individual patients and the nation, a new analysis shows. From 1990 to 2008, spending on cancer care soared to more than $90 billion from $27 billion. The increase was driven by the rising costs of sophisticated new drugs, robotic surgeries and radiation techniques, as well as the growing number of patients who are eligible to take them, says Peter Bach of New York's Memorial Sloan-Kettering Cancer Cancer, co-author of an analysis in today's Journal of the American Medical Association.

18 Mar 2010

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH) for the further study and characterization of a back-up series of compounds related to its novel antibacterial, ACH-702.

18 Mar 2010

Modulating body's inflammatory response may help fight serious infection

Treating virulent influenza, sepsis, and other potentially deadly infections long has focused on looking for ways to kill viruses and bacteria. But new research from the University of Utah and Utah State University shows that modulating the body's own overeager inflammatory response to infection may help save more lives.

18 Mar 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

China’s healthcare reform one year later

In April 2009, the Chinese government announced the guidelines for healthcare reform, with the core principle of providing universal healthcare services to the country's 1.3 billion population. China will invest 850 billion RMB ($124 billion) on healthcare from 2009 to 2011, further stimulating demand for medical devices, in what is already one of the world's fastest growing markets for medical technology. One year later, a number of new regulations and guidelines are in place, which are beginning to reshape the structure of the Chinese healthcare industry.

18 Mar 2010

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller.

18 Mar 2010

New combination drug treatment for parasitic intestinal roundworms shows promise

Several drugs currently in use or in development control parasitic worms in the same way. That concerns health workers In developing countries where reinfestations often require repeated treatments. If worms develop resistance to one drug, the other treatments would likely fail as well.

18 Mar 2010

Evaluating all Medicare plan options can reduce healthcare costs

Nearly 8 million former workers have disabilities so severe that they rely on Social Security Disability Insurance benefits, and an estimated 3.3 million more will apply for disability benefits this year. For these people and others suffering from serious conditions and disabilities, taking the right steps quickly to manage costs is essential for their financial and health well-being, according to Allsup, a nationwide provider of Social Security disability representation and Medicare plan selection services.

18 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

Drugs News and Research

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

As reform hangs in balance, policy benefits continue to be discussed

Acne drug prevents HIV breakout

Health care fraud, prescription theft lead to significant losses

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Therapeutic may not be effective on trauma patients with undiagnosed Helicobacter infections

Study finds the cost of cancer care is skyrocketing

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Modulating body's inflammatory response may help fight serious infection

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

China’s healthcare reform one year later

Alpharma to pay $42.5M for settling alleged Kadian kickback scheme

New combination drug treatment for parasitic intestinal roundworms shows promise

Evaluating all Medicare plan options can reduce healthcare costs

Genes allowing opium poppy to make codeine and morphine discovered

NexACT technology demonstrates ability to deliver Taxol subcutaneously

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News